177 related articles for article (PubMed ID: 30935250)
1. Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells.
Kamrani A; Mehdizadeh A; Ahmadi M; Aghebati-Maleki L; Yousefi M
Expert Opin Ther Targets; 2019 May; 23(5):447-456. PubMed ID: 30935250
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.
Shabani M; Naseri J; Shokri F
Expert Opin Ther Targets; 2015 Jul; 19(7):941-55. PubMed ID: 25835638
[TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia.
Aghebati-Maleki L; Shabani M; Baradaran B; Motallebnezhad M; Majidi J; Yousefi M
Biomed Pharmacother; 2017 Apr; 88():814-822. PubMed ID: 28160756
[TBL] [Abstract][Full Text] [Related]
4. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
[TBL] [Abstract][Full Text] [Related]
5. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention.
Menck K; Heinrichs S; Baden C; Bleckmann A
Cells; 2021 Jan; 10(1):. PubMed ID: 33445713
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
7. ROR1-targeting switchable CAR-T cells for cancer therapy.
Peng H; Nerreter T; Mestermann K; Wachter J; Chang J; Hudecek M; Rader C
Oncogene; 2022 Aug; 41(34):4104-4114. PubMed ID: 35859167
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.
Rydzek J; Nerreter T; Peng H; Jutz S; Leitner J; Steinberger P; Einsele H; Rader C; Hudecek M
Mol Ther; 2019 Feb; 27(2):287-299. PubMed ID: 30573301
[TBL] [Abstract][Full Text] [Related]
9. Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors.
Wang D; Yang L; Yu W; Zhang Y
Expert Opin Investig Drugs; 2019 Oct; 28(10):903-916. PubMed ID: 31560229
[No Abstract] [Full Text] [Related]
10. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
11. In-Silico Drug discovery approach targeting receptor tyrosine kinase-like orphan receptor 1 for cancer treatment.
Nath O; Singh A; Singh IK
Sci Rep; 2017 Apr; 7(1):1029. PubMed ID: 28432357
[TBL] [Abstract][Full Text] [Related]
12. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
13. Targeting ROR1 identifies new treatment strategies in hematological cancers.
Karvonen H; Niininen W; Murumägi A; Ungureanu D
Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
[TBL] [Abstract][Full Text] [Related]
14. Hematological malignancies and molecular targeting therapy.
Shimada A
Eur J Pharmacol; 2019 Nov; 862():172641. PubMed ID: 31493406
[TBL] [Abstract][Full Text] [Related]
15. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
16. Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.
Cioccio J; Claxton D
Expert Opin Investig Drugs; 2019 Apr; 28(4):337-349. PubMed ID: 30775933
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
18. ROR-Family Receptor Tyrosine Kinases.
Stricker S; Rauschenberger V; Schambony A
Curr Top Dev Biol; 2017; 123():105-142. PubMed ID: 28236965
[TBL] [Abstract][Full Text] [Related]
19. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
20. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
